Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Mauna Kea Technologies    MKEA   FR0010609263

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

MAUNA KEA TECH : MAUNA KEA TECHNOLOGIES ANNOUNCES CELLVIZIO'S VERY STRONG PRESENCE AT THREE MAJOR GASTROENTEROLOGY CONFERENCES IN THE USA, EUROPE AND JAPAN

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/15/2013 | 06:09pm CEST
MAUNA KEA TECHNOLOGIES ANNOUNCES CELLVIZIO'S VERY STRONG PRESENCE AT THREE MAJOR GASTROENTEROLOGY CONFERENCES IN THE USA, EUROPE AND JAPAN 30 presentations dedicated to the benefits of optical biopsy at the same time on 3 continents Paris, Berlin, Tokyo, San Diego, October 15, 2013 - Mauna Kea Technologies (NYSE Euronext: MKEA FR0010609263), leader in the optical biopsy market and maker of Cellvizio, the fastest way to see cancer, today announced its strong participation in 3 major congresses around the world: the United European Gastroenterology Week (UEGW) in Berlin, the annual congress of the American College of Gastroenterology in San Diego, and the Japanese Digestive Disease Week in Tokyo. United European Gastroenterology Week (UEGW), Berlin, 12 to 16 October 2013

More than 20 study results on patient management optimization thanks to Cellvizio will be presented at this congress hosting 14,000 attendees, the most important and prestigious in gastroenterology in Europe. A large portion of these results will be on pancreatic cyst management with the AQ-Flex probe, which was recently cleared by FDA and launched in the USA.
A large number of attendees could also see a live demonstration of Cellvizio in the management of Barrett's Esophagus performed by Pr. Emmanuel Coron from CHU Nantes, France, from the Sana-Klinikum Lichtenhagen, where Cellvizio was used to orient the patient's therapeutic options.

Japanese Digestive Disease Week (JDDW), Tokyo, 8 to 12 October 2013

With more than 20 000 participants, this congress provided a strong exposure for Cellvizio to the Japanese market, a pioneering and very important one for digestive endoscopy. Several physicians from Japan and other Asian countries presented orally their results with Cellvizio on Asian populations, in particular on pancreatic cyst management.

Annual Congress of the American College of Gastroenterology (ACG), San Diego, 13 to 15 October 2013

Mauna Kea Technologies also has a strong presence at the ACG meeting, one of the most important for gastroenterology in the USA, the most important market for the Company today. Optical Biopsy was in the spotlight with more than 10 presentations as well as a hands-on training session on Cellvizio. Physicians could also discover how easy optical biopsy interpretation was thanks to a dedicated station.
Sacha Loiseau, CEO of Mauna Kea Technologies, declared: « The simultaneous presence of Mauna Kea Technologies on these 3 major gastroenterology congresses in Europe, Asia and the United-States, once more underlines the broad reach and the growing recognition of the value that Cellvizio optical biopsy brings to patients, physicians and healthcare systems around the world ».

About Mauna Kea Technologies

Mauna Kea Technologies is a global firm specializing in medical equipment used to carry out optical biopsies, and is market leader in endomicroscopy. The company designs, develops and sells innovative imaging tools that can detect cellular abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product, Cellvizio®, a confocal endomicroscopy system that uses a mini-probe, provides doctors and researchers with high-resolution cellular images of internal tissues. Large-scale, international multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early signs of disease and make immediate treatment decisions. Cellvizio was designed to help physicians make diagnoses, treat patients more effectively and reduce hospital costs, and is compatible with most types of endoscope. It has

1

received 510(k) authorization from the US Food and Drug Administration and the CE mark in Europe for use in gastrointestinal and pulmonary equipment.

For more information on Mauna Kea Technologies, please visit www.maunakeatech.com

Mauna Kea Technologies

Eric Cohen

V ice-President Finance

Tel: +33 (0)1 70 08 09 70

[email protected]

France and Europe

ALIZE RP

Caroline Carmagnol / Christian Berg

Tel: +33 (0)6 64 18 99 59 / +33 (0)1 70 22 53 86 [email protected] / [email protected]

NEWCAP

Investor Relations & Financial Communications

Florent Alba / Pierre Laurent Tel: +33 (0)1 44 71 94 94 [email protected]

2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MAUNA KEA TECHNOLOGIES
03/28 MAUNA KEA TECH : New Peer-Reviewed Publication Reports Further External Validati..
03/23 MAUNA KEA TECH : Technologies confirms its eligibility to the French PEA-PME inv..
03/21 MAUNA KEA TECH : Technologies to announce 2016 full yea results on march 23, 201..
03/20MAUNA KEA TECHNOLOGIES SAS : annual earnings release
03/09 MAUNA KEA TECHNOLOGIES : Superiority of Endomicroscopy for the Diagnosis of Gast..
03/02 MAUNA KEA TECH : Superiority of Endomicroscopy for the Diagnosis of Gastric Canc..
02/16 OPTISCAN IMAGING : Patent Issued for Reflective Optical Objective (USPTO 9563044..
01/03 MAUNA KEA TECH : Half-yearly report on the liquidity contract with Gilbert Dupon..
2016 MAUNA KEA TECH : PERSEE Study demonstrates applicability of Cellvizio in surgica..
2016 MAUNA KEA TECH : Technologies Reports third quarter 2016 Sales
More news
Sector news : Advanced Medical Equipment & Technology - NEC
06/22DJROYAL PHILIPS : Philips to Buy Electrical Geodesics for GBP29 Million
06/19 PERKINELMER : to buy Germany's Euroimmun for about $1.3 billion
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/17 PHILIPS CEO : uptake of connected care products progressing slowly
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
06/21 Mauna Kea Technologies SA (MKEAF) Presents At JMP Securities Life Sciences Co..
04/19 Mauna Kea Technologies reports Q1 results
03/23 Mauna Kea Technologies reports FY results
2016 Mauna Kea Technologies reports Q3 revenue
2016 Mauna Kea TechnologiesO reports Q2 results
Advertisement
Financials (€)
Sales 2017 14,7 M
EBIT 2017 -9,40 M
Net income 2017 -9,53 M
Debt 2017 0,80 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,53x
EV / Sales 2018 4,27x
Capitalization 51,1 M
More Financials
Chart MAUNA KEA TECHNOLOGIES
Duration : Period :
Mauna Kea Technologies Technical Analysis Chart | MKEA | FR0010609263 | 4-Traders
Full-screen chart
Technical analysis trends MAUNA KEA TECHNOL...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 3,85 €
Spread / Average Target 44%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Sacha Loiseau President, Chief Executive Officer & Director
Chris D. McFadden Chairman
John J. Soto Chief Operating Officer
Benoît Jacheet Chief Financial Officer & Head-Investor Relations
François Lacombe Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MAUNA KEA TECHNOLOGIES-11.59%57
THERMO FISHER SCIENTIF..23.63%68 244
DANAHER10.43%60 686
BOSTON SCIENTIFIC CORP..29.91%38 480
INTUITIVE SURGICAL49.64%34 960
ROYAL PHILIPS13.22%34 550
More Results